On Thursday, Following Stocks were among the “Top 100 Losers” of U.S. Stock Market: ASML Holding NV (NASDAQ:ASML), RXi Pharmaceuticals Corporation (NASDAQ:RXII), Aeterna Zentaris Inc. (NASDAQ:AEZS), Novavax, Inc. (NASDAQ:NVAX)
ASML Holding NV (NASDAQ:ASML), with shares declined -5.30%, closed at $99.08.
RXi Pharmaceuticals Corporation (NASDAQ:RXII), with shares dropped -5.15%, settled at $0.749, hitting new 52-week low of $0.73.
Aeterna Zentaris Inc. (NASDAQ:AEZS), with shares dipped -5.05%, and closed at $0.545.
Novavax, Inc. (NASDAQ:NVAX), plummeted -5.01%, and closed at $7.58.
Latest NEWS regarding these Stocks are depicted underneath:
ASML Holding NV (NASDAQ:ASML)
On the very First Day of this Month, ASML Holding NV (ASML), discovered unauthorized access to a limited portion of its IT systems. ASML took immediate steps to contain the breach and is conducting an ongoing investigation. The time between the break-in and the discovery by ASML IT staff was short. At this time it appears that only a limited amount of data has been accessed. ASML has not found any evidence that valuable files, either from ASML or our customers and suppliers, have been compromised. We cannot be certain about the identity of the hackers.
ASML, like any other leading organization, is subject to cybersecurity attacks. The company take knowledge protection very seriously and constantly work to improve our defenses against hacking attempts and our detection capabilities.
ASML Holding N.V. engages in the development, production, marketing, sale, and servicing of advanced semiconductor equipment systems with a focus on lithography related systems worldwide.
RXi Pharmaceuticals Corporation (NASDAQ:RXII)
RXi Pharmaceuticals Corporation (RXII), declared at the annual meeting of the American Academy of Dermatology in San Francisco, several noteworthy advancements within its dermatological programs.
A biotechnology corporation focused on discovering and developing innovative therapeutics addressing high-unmet medical needs primarily in the area of dermatology and ophthalmology also declared that it will report financial results for the fourth quarter and year ended December 31, 2014 on Monday, March 30, 2015 after the close of the U.S. financial markets.
RXi Pharmaceuticals Corporation, a biotechnology corporation, focuses on discovering, developing, and commercializing therapies based on its proprietary, next-generation RNA interference (RNAi) platform.
Aeterna Zentaris Inc. (NASDAQ:AEZS)
Formerly on March 17, Aeterna Zentaris Inc. (AEZS), stated financial and operating results as at and for the fourth quarter and the year ended December 31, 2014.
Net revenue (loss) for the three-month period and the year ended December 31, 2014 was $4.2 million and $(16.6) million, or $0.06 and $(0.28) per basic and diluted share, respectively, as contrast to $(8.2) million and $6.8 million, or $(0.22) and $0.24 per basic and diluted share, for the same periods in 2013. The rise in net revenue for the three-month period ended December 31, 2014, as contrast to the same period in 2013, is due largely to higher comparative net finance revenue, offset partially by higher comparative operating expenses and by lower net revenue from suspended operations. The decrease in net revenue for the year ended December 31, 2014, as contrast to the same period in 2013, is due largely to the higher loss from operations and to lower net revenue from suspended operations, partially offset by higher comparative net finance revenue.
Cash and cash equivalents totaled $34.9 million as at December 31, 2014, as contrast to $43.2 million as at December 31, 2013.
David Dodd, Aeterna Zentaris Chairman and CEO, commented, “During 2014, we achieved noteworthy progress in the implementation of our strategy of transitioning into a commercially operating specialty biopharmaceutical corporation, as we put our commercial structure in place, built a full-time contract sales force of 19 representatives, signed a co-promotion contract with ASCEND and started selling its product EstroGel® in our specific territories in the US. We are ongoing to evaluate potential in-licensing and/or attainment opportunities, in addition to additional co-promotional arrangements related to marketed products, in order to grow our commercial activities. We are also proud of our partnership contract for our lead oncology compound, zoptarelin doxorubicin, with Sinopharm A-Think for China, one of the largest markets in the world. With regards to our ZoptEC Phase 3 study in endometrial cancer with zoptarelin doxorubicin, we are very happy with the progress of patient recruitment as we now have over 400 patients enrolled in the trial out of an predictable total of 500, which is in line with our projections. Therefore, we expect that at this rate, a first interim analysis of the trial should be secured in the first half of the current year, and patient recruitment should be accomplished by year-end. As for Macrilen™, following the FDA’s Complete Response Letter, we intend to make a decision in the near term on our different options for this product in the evaluation of AGHD. For 2015, we remain fully focused on becoming a growth-oriented, commercially operating specialty biopharmaceutical organization, while ongoing to develop key late-stage product candidates in our existing pipeline, such as our novel targeted anti‑cancer agent, zoptarelin doxorubicin.”
Aeterna Zentaris Inc., a specialty biopharmaceutical corporation, engages in developing and commercializing novel treatments in oncology, endocrinology, and women’s health.
Novavax, Inc. (NASDAQ:NVAX)
Novavax, Inc. (NVAX), declared that it has priced an underwritten public offering of 24,137,931 shares of ordinary stock at a price to the public of $7.25 per share for gross proceeds of about $175 million. Novavax anticipates to receive net proceeds, after deducting the underwriting discount, of about $165 million from the offering. In connection with this offering, Novavax has granted the underwriters a 30-day option to purchase up to an additional 3,620,689 shares of its ordinary stock. If the underwriters exercise this option in full, Novavax will have sold 27,758,620 shares of its ordinary stock.
Novavax intends to use the net proceeds from this offering for the advancement of its lead vaccine candidates, counting the preparation and potential initiation of Phase 3 clinical trials of its elderly RSV and maternal RSV programs, in addition to its other clinical and preclinical research programs and general corporate purposes, counting working capital, product development, manufacturing and process development expenditures and capital expenditures, in addition to attainments and other planned purposes. The offering is predictable to close on or about March 31, 2015, subject to the satisfaction of customary closing conditions.
J.P. Morgan and Citigroup are acting as joint book-running managers of the offering. Piper Jaffray & Co. and Wedbush PacGrow are acting as Co-Lead Managers, Janney Montgomery Scott and Ladenburg Thalmann are acting as Co-Managers.
Novavax, Inc., a clinical-stage vaccine corporation, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The corporation produces its vaccines using its proprietary recombinant nanoparticle vaccine technology.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
